Investors Survive Defendants' Motion to Dismiss in Securities
Class Action
Juno is currently the subject of a federal securities class action
alleging that between June 4, 2016 and November 22, 2016, Juno officials
understated the risks associated with JCAR015. In July 2016, in addition
to finally disclosing several patient deaths associated with the drug,
Juno revealed that the FDA issued a clinical hold. On June 14, 2017,
U.S. District Judge Ricardo Martinez issued an order in the securities
class action denying defendants' motion to dismiss.
Juno Shareholders Have Legal Options
Concerned shareholders who would like more information about their
rights and potential remedies can contact attorney Leonid Kandinov at
(800) 350-6003, [email protected],
or via the shareholder
information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder
rights law. The firm represents individual and institutional investors
in shareholder derivative and securities class action lawsuits, and has
helped its clients realize more than $1 billion of value for themselves
and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170922005691/en/
[ Back To TMCnet.com's Homepage ]